|
|
9 Av, des Montboucons
25 000 Besancon, France
phone:
+33 3 81 53 22 43
fax:
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
www.trodmedical.com |
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Trod Medical develops single-use surgical devices . |
 |
| Management |
| Andre Faure, MD, President / CEO; Manfred Sablowski, Vice President & Chief Operating Officer; Brook R. Peterson, President & CEO of Trod Medical USA
|
|
|
|
|
| Keywords |
| Urology, Prostate, Oncology, Cancer |
|
|
|
|
Description |
| Trod Medical is a medical start up company offering a surgical instrument for the treatment of prostate cancers and a flexible endoscope for the destruction of localized lung tumors, through radio frequency. |
 |
| Technology / Differentiation |
| Encage is its new,patented single use product allowing for controlled and precise percutaneous tissue destruction. The product aims at treating prostrate cancer through radio frequency under image guidance, also applicable for kidney and liver tumor ablation. |
 |
| Market / Customers |
The company has a target market revenue of approximately EUR 1 bilion. The major competitor is Brachytherapy, a more expensive treatment than Encage technology.
|
 |
| Competitors / Substitutes / Alternatives |
Brachytherapy, a competitor technology, which is currently facing a declining market and offers a less effective and more expensive treatment in comparison to Encage.
|
 |
| Status |
| Trod Medical needs EUR 5.2 million for setting up clinical protocols, obtaining CE mark and achieving sales targets. Encage is awaiting FDA 510K clearance. Its expected valuation after 3 - 3.5 years is around EUR 150 million. The company's plans are to look for a buyer in the major medical devices area or go public. |
 |
|
|
|
|